• Press Release

"Minerva" Super Computer Ushers New Era Of Precision Medicine At Mount Sinai

Sophisticated algorithms analyze data to develop predictive models of disease in order to better diagnose and treat patients

  • New York, NY
  • (April 17, 2013)

Ushering a new era of "precision medicine," Mount Sinai is one of the first academic medical centers in the United States to build and operate a supercomputer.  Named after the Roman goddess of wisdom and medicine, "Minerva," uses sophisticated computer algorithms to analyze data in order to develop predictive models of disease that can better help diagnose and treat patients.  

After a full year of operation, the $3 million computer is a large step forward in building a significant computational and data-intensive infrastructure geared specifically for genomics. Built on-site by Mount Sinai's Department of Scientific Computing, Minerva analyzes the growing "digital universe", including genomic and phenotypic data, as well information from electronic medical records (EMR).  In fact, it has already analyzed hundreds of human genome sequences with a projection of hundreds of thousands every year.   With thousands of processing cores working in unison, and tens of terabytes of memory, the computer can perform complex and sophisticated tasks quickly and with more precision than ever before.  

"With Minerva, Mount Sinai has the ability to quickly analyze genomic patterns to provide a greater understanding of the causes of disease and how to personalize treatments according to an individual's genetic composition," said Dennis S. Charney, MD, Dean of the Icahn School of Medicine at Mount Sinai. "The supercomputer is able to accomplish real-time visualization of advanced molecular models, promoting drug development and allowing us to test the effects of molecular variations on different receptors in the body."  

The supercomputer also stores information from Mount Sinai's biobank, or BioME, a collection of more than 25,000 individuals' DNA and plasma samples that are stored in a way that protects patients' privacy while allowing research to be performed.  Funded by the Charles R. Bronfman Institute for Personalized Medicine, the biobank accesses a broad range of genetic and environmental information on patients who have agreed to lifelong participation.  

"The supercomputer is helping us better understand and foresee the course of disease for each patient  -- and to identify the outcome to a particular therapeutic intervention in advance," said Patricia Kovatch, Associate Dean for Scientific Computing at Mount Sinai Medical Center and the engineer who constructed Minerva.  "Thus, using genomic data, information from our biobank as well as complex simulations of molecules, we are able to enhance personalized medicine to a degree that has never been done before."  

Eric Schadt, PhD, Mount Sinai's Director of the Institute for Genomics and Multiscale Biology, cited the need for Minerva in critical areas of research that is already underway.

"In order to analyze and integrate all the different data dimensions over the population, and build predictive models of disease, we need the supercomputer.  With the infrastructure we're creating, and the people we've recruited, combined with the resources already available at Mount Sinai, we are coming together to form a new epicenter of research on personalized medicine and the new biology."

"Few research centers have the type of computing infrastructure to allow advanced modeling that Mount Sinai can now do on-site.  Along with other advances in genetics and some recent outstanding additions to our faculty, Minerva further cements Mount Sinai's reputation at the forefront of the ‘precision medicine' movement," said Dr. Charney.

Joseph Buxbaum, PhD, Director of the Seaver Autism Center for Research and Treatment, says Minerva's supercomputing capacity plays a key role in analyzing data gathered as part of the Autism Sequencing Consortium, a multinational collaboration where all the 22,000 genes in humans will be sequenced in thousands of individuals with autism spectrum disorder.  "The consortium plans to have such data for as many as 30,000 people – including controls – over the next three years, and we anticipate that this will result in the discovery of several hundred autism genes.  Without Minerva's computational power, a project of this scope would simply not be feasible."

To date, tens of millions of core processing hours of work has been done by Minerva, added Kovatch.  "The computer has helped scientists publish more than 25 research papers in less than a year.  Minerva helps scientists analyze their data quicker than ever before, as well as complete more complex tasks simultaneously.  The end result is that more science, even basic science, is done quicker and more efficiently."


About the Mount Sinai Health System

Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, over 400 outpatient practices, nearly 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.

Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. We are consistently ranked by U.S. News & World Report's Best Hospitals, receiving high "Honor Roll" status, and are highly ranked: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. U.S. News & World Report’s “Best Children’s Hospitals” ranks Mount Sinai Kravis Children's Hospital among the country’s best in 4 out of 10 pediatric specialties. The Icahn School of Medicine at Mount Sinai is one of three medical schools that have earned distinction by multiple indicators: It is consistently ranked in the top 20 by U.S. News & World Report's "Best Medical Schools," aligned with a U.S. News & World Report "Honor Roll" Hospital, and top 20 in the nation for National Institutes of Health funding and top 5 in the nation for numerous basic and clinical research areas. Newsweek’s “The World’s Best Smart Hospitals” ranks The Mount Sinai Hospital as No. 1 in New York and in the top five globally, and Mount Sinai Morningside in the top 20 globally.

For more information, visit https://www.mountsinai.org or find Mount Sinai on FacebookTwitter and YouTube.